Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome

Internal Medicine

Volumn 49, Issue 19, 2010, Pages 2065-2070

  Takei, Takashi ^a   Itabashi, Mitsuyo ^a   Tsukada, Misao ^a   Sugiura, Hidekazu ^a   Moriyama, Takahito ^a   Kojima, Chiari ^a   Shiohira, Shunji ^a   Shimizu, Ari ^a   Karasawa, Kazunori ^a   Amemiya, Nobuyuki ^a   Kawanishi, Kunio ^a   Ogawa, Tetsuya ^a   Uchida, Keiko ^a   Tsuchiya, Ken ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Bone mineral density; Minimal change nephritic syndrome; Risedronate; Steroid induced osteoporosis

Indexed keywords

ALFACALCIDOL; BENET; CYCLOSPORIN; METHYLPREDNISOLONE; PREDNISOLONE; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; LUMBAR SPINE; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; MONOTHERAPY; NEPHROTIC SYNDROME; OPEN STUDY; PARALLEL DESIGN; PRIMARY PREVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; UNSPECIFIED SIDE EFFECT;

ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; NEPHROSIS, LIPOID; OSTEOPOROSIS; PREDNISOLONE; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 77958093254     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3707     Document Type: Article

References (39)

1. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG. Adult-onset nephritic syndrome: a long-term follow-up. Kidney Int 29: 1215-1223, 1986.
2. Korbet S, Schwartz MM, Lewis EJ. Minimal-change glomerulopathy of adulthood. Am J Nephrol 8: 291-297, 1988.
3. Eastell R. Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. J Intern Med 237: 439-447, 1995.
4. Sambrook PN. Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 15: 1645-1649, 2000.
5. Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol 14: 199-206, 1996.
6. Jardinet D, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Houssiau FA. Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford) 39: 389-392, 2000.
7. Gula S, Godbole M, Singh U, Gulati K, Srivastava A. Are children with idiopathic nephritic syndrome at risk for metabolic bone disease? Am J Kidney Dis 41: 1163-1169, 2003.
8. Lang P, Steiger P, Faulkner K, Guller L, Genant HK. Osteoporosis: Current techniques and recent development in quantitative bone densitometry. Radiol Clin North Am 29: 49-76, 1991.
9. Eberhardt AW, Yeager-Jones A, Blair HC. Regional trabecular bone matrix degeneration and osteocyte death in femora of glucocorticoid-treated rabbits. Endocrinology 142: 1333-1340, 2001.
10. Mirzaei S, Zajicek HK, Knoll P, et al. Effect of rocaltrol on bone mass in patients with pulmonary disease treated with corticosteroids. J Asthma 40: 251-255, 2003.
11. Loddenkemper K, Grauer A, Burmester GR, Buttgereit F. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases. Clin Exp Rheumatol 21: 19-26, 2003.
12. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69: 242-247, 2001.
13. Reid DM, Devogelaer JP, Saag K, et al. HORIZON investigators: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373: 1253-1263, 2009.
14. Kim SD, Cho BS. Pamidronate therapy for preventing steroidinduced osteoporosis in children with nephropathy. Nephron Clin Pract 102: c81-c87, 2006.
15. Kikuchi Y, Imakiire T, Yamada M, et al. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. Nephrol Dial Transplant 22: 1593-1600, 2007.
16. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 15: 454-457, 2003.
17. Adami S, Fossaluzza V, Rossini M, et al. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Miner 15: 73-81, 1991.
18. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112: 352-364, 1990.
19. Lettgen B, Jeken C, Reiners C. Influence of steroid medication on bone mineral density in children with nephrotic syndrome. Pediatr Nephrol 8: 667-670, 1994.
20. Matsumoto H, Ishihara K, Hasegawa T, Umeda B, Niimi A, Hino M. Effects of inhaled steroids and short courses of oral steroids on bone mineral density in asthmatic patients: a 4-year longitudinal study. Chest 120: 1468-1473, 2001.
21. Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11: 331-337, 2000.
22. von Tirpitz C, Klaus J, Bruckel J, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 12: 19-24, 2000.
23. Harris RC, Ismail N. Extrarenal complications of the nephrotic syndrome. Am J Kidney Dis 23: 477-497, 1994.
24. Goldstein DA, Haldimann B, Shermann D, Norman AW, Massry SG. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 52: 116-121, 1981.
25. Lambert PW, Deoreo PB, Fu IY, et al. Urinary and plasma vitamin D3 metabolites in the nephrotic syndrome. Metab Bone Dis Relat Res 4: 7-15, 1982.
26. Tessitore N, Bonucci E, D'Angelo A, et al. Bone histology and calcium metabolism in patients with nephrotic syndrome and normal or reduced renal function. Nephron 37: 153-159, 1984.
27. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337: 382-387, 1997.
28. Saag KG, Enkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339: 292-299, 1998.
29. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents coticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42: 2309-2318, 1999.
30. de Nijis RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15: 589-602, 2004.
31. Yonemura K, Fukasawa H, Fujigaki Y, Hishida A. Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine. Am J Kidney Dis 43: 53-60, 2004.
32. Nakayamada S, Okada Y, Saito K, Tanaka Y. Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. J Rheumatol 31: 163-166, 2004.
33. Mittal SK, Dash SC, Tiwari SC, Agarwal SK, Saxena S, Fishbane S. Bone histology in patients with nephrotic syndrome and normal renal function. Kidney Int 55: 1912-1919, 1999.
34. Rogers MJ, Frith JC, Luckman SP, et al. Molecular mechanisms of action of bisphosphonates. Bone 24: 73S-79S, 1999.
35. Nawata H, Soen S, Takayanagi R, et al. Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis: Guidelines on the management and treatment of glucocorticoidinduced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23: 105-109, 2005.
36. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13: 777-787, 2002.
37. Takei T, Koike M, Suzuki K, et al. The characteristics of relapse in adult-onset minimal-change nephrotic syndrome. Clin Exp Nephrol 11: 214-217, 2007.
38. Kelly PJ, Hopper JL, Macaskill GT, Poccock NA, Sambrook PN, Eisman JA. Genetic factors in bone turnover. J Clin Endocrinol Metab 72: 808-813, 1991.
39. Tokita A, Kelly PJ, Nguyen TV, et al. Genetic influences on type I collagen synthesis and degradation: further evidence for genetic regulation of bone turnover. J Clin Endocrinol Metab 78: 1461-1466, 1994.